Timo Väisänen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Timo Väisänen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Aki Manninen
Disease Networks Research Unit, Faculty of Biochemistry and Molecular Medicine, Biocenter Oulu, University of Oulu, Oulu, Finland
2 shared publications - Fredrik Wärnberg
Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , Gothenburg
2 shared publications Guillermo Martínez-Nieto
2 shared publications- Gunilla Rask
Department of Medical Biosciences/Pathology, Umeå University, Umeå, Sweden
2 shared publications - Heli Ruotsalainen
Oulu Center for Cell-Matrix Research, Faculty of Biochemistry and Molecular Medicine
2 shared publications - Hellevi Peltoketo
University of Oulu
2 shared publications
Latest Publications
- Open Access
- 12 June 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (15)
Corrigendum to Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models
- 12 June 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (15)
Open AccessCorrigendum to Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models
- Open Access
- 15 September 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (18)
Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models
The tumor extracellular matrix (ECM) critically regulates cancer progression and treatment response. Expression of the basement membrane component collagen XVIII (ColXVIII) is induced in solid tumors, but its involvement in tumorigenesis has remained elusive. We show here that ColXVIII was markedly upregulated in human breast cancer (BC) and was closely associated with a poor prognosis in high-grade BCs. We discovered a role for ColXVIII as a modulator of epidermal growth factor receptor tyrosine kinase (ErbB) signaling and show that it forms a complex with ErbB1 and -2 (also known as EGFR and human epidermal growth factor receptor 2 [HER2]) and α6-integrin to promote cancer cell proliferation in a pathway involving its N-terminal portion and the MAPK/ERK1/2 and PI3K/AKT cascades. Studies using Col18a1 mouse models crossed with the mouse mammary tumor virus–polyoma virus middle T antigen (MMTV-PyMT) mammary carcinogenesis model showed that ColXVIII promoted BC growth and metastasis in a tumor cell–autonomous manner. Moreover, the number of mammary cancer stem cells was significantly reduced in the MMTV-PyMT and human cell models upon ColXVIII inhibition. Finally, ablation of ColXVIII substantially improved the efficacy of ErbB-targeting therapies in both preclinical models. In summary, ColXVIII was found to sustain the stemness properties of BC cells and tumor progression and metastasis through ErbB signaling, suggesting that targeting ColXVIII in the tumor milieu may have important therapeutic potential.
- 15 September 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (18)
Open AccessTargeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models
The tumor extracellular matrix (ECM) critically regulates cancer progression and treatment response. Expression of the basement membrane component collagen XVIII (ColXVIII) is induced in solid tumors, but its involvement in tumorigenesis has remained elusive. We show here that ColXVIII was markedly upregulated in human breast cancer (BC) and was closely associated with a poor prognosis in high-grade BCs. We discovered a role for ColXVIII as a modulator of epidermal growth factor receptor tyrosine kinase (ErbB) signaling and show that it forms a complex with ErbB1 and -2 (also known as EGFR and human epidermal growth factor receptor 2 [HER2]) and α6-integrin to promote cancer cell proliferation in a pathway involving its N-terminal portion and the MAPK/ERK1/2 and PI3K/AKT cascades. Studies using Col18a1 mouse models crossed with the mouse mammary tumor virus–polyoma virus middle T antigen (MMTV-PyMT) mammary carcinogenesis model showed that ColXVIII promoted BC growth and metastasis in a tumor cell–autonomous manner. Moreover, the number of mammary cancer stem cells was significantly reduced in the MMTV-PyMT and human cell models upon ColXVIII inhibition. Finally, ablation of ColXVIII substantially improved the efficacy of ErbB-targeting therapies in both preclinical models. In summary, ColXVIII was found to sustain the stemness properties of BC cells and tumor progression and metastasis through ErbB signaling, suggesting that targeting ColXVIII in the tumor milieu may have important therapeutic potential.